The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisai and Biogen’s Leqembi. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results